Niels Reinmuth

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 3

Top Topics

Brain Metastases

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Niels Reinmuth, Oscar Juan Vidal, Dariusz Mirosław Kowalski, Maciej Bryl, Anna Kryzhanivska, David Vicente, Zsolt Horváth, Gabriella Gálffy, Eszter Csánky, Zsolt Pápai Székely, Ihor Vynnychenko, Jon Armstrong, Tapashi Dalvi, Mingchao Xie, Sonia Iyer, Yashaswi Shrestha, Haiyi Jiang, Igor Bondarenko
Novel Combinations of Immunotherapies or DNA Damage Repair Inhibitors in Platinum-Refractory Extensive-Stage Small-Cell Lung Cancer: The Phase II BALTIC Study. Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
Luis G Paz-Ares, Marina-Chiara Garassino, Yuanbin Chen, Niels Reinmuth, Katsuyuki Hotta, Artem Poltoratskiy, Dmytro Trukhin, Maximilian Johannes Hochmair, Mustafa Özgüroğlu, Jun Ho Ji, Galina Statsenko, Nikolay Vladimirov Conev, Igor Bondarenko, Libor Havel, György Losonczy, Mingchao Xie, Zhongwu Lai, Nadia Godin-Heymann, Helen Mann, Haiyi Jiang, Yashaswi Shrestha, Jonathan Wade Goldman
Durvalumab ± tremelimumab + platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): outcomes by PD-L1 expression and tissue tumor mutational burden. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Niels Reinmuth, Maciej Bryl, Igor Bondarenko, Kostas Syrigos, Vladimir Vladimirov, Manuela Zereu, Angel H Bair, Fiona Hilton, Katherine Liau, Kazuo Kasahara
PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin®), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 33 (5) (2020)